Survivin as a Therapeutic Target for Neuroendocrine Neoplasms

Hane, Yuma; Tsuchikawa, Takahiro; Nakamura, Toru et al.

Neuroendocrinology, 2025, 115(3-4), 295-307

Permalink : https://hdl.handle.net/2115/97446

このアイテムのアクセス数:52件（2026-07-17 21:05 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
huscap_manuscript pdf 5.00 MB 36

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/97446
タイトル
Survivin as a Therapeutic Target for Neuroendocrine Neoplasms
著者
Hane, Yuma ; Tsuchikawa, Takahiro ; Nakamura, Toru ; Hatanaka, Kanako C. ; Sasaki, Katsunori ; Kawai, Noriko ; Takeuchi, Shintaro ; Tanaka, Kimitaka ; Nakanishi, Yoshitsugu ; Asano, Toshimichi ; Noji, Takehiro ; Shichinohe, Toshiaki ; Hatanaka, Yutaka ; Hirohshi, Yoshihiko ; Torigoe, Toshihiko ; Hirano, Satoshi
著者名
Hane, Yuma
e-Rad_Researcher
50507572
著者名
Tsuchikawa, Takahiro
e-Rad_Researcher
70645796
著者名
Nakamura, Toru
著者名
Hatanaka, Kanako C.
e-Rad_Researcher
60336394
著者名
Sasaki, Katsunori
著者名
Kawai, Noriko
著者名
Takeuchi, Shintaro
e-Rad_Researcher
10758642
著者名
Tanaka, Kimitaka
e-Rad_Researcher
40447058
著者名
Nakanishi, Yoshitsugu
e-Rad_Researcher
10756688
著者名
Asano, Toshimichi
e-Rad_Researcher
10739296
著者名
Noji, Takehiro
e-Rad_Researcher
70374353
著者名
Shichinohe, Toshiaki
e-Rad_Researcher
30589924
著者名
Hatanaka, Yutaka
著者名
Hirohshi, Yoshihiko
著者名
Torigoe, Toshihiko
e-Rad_Researcher
50322813
著者名
Hirano, Satoshi
言語
英語
キーワード
Neuroendocrine neoplasms
Survivin
Prognosis
Metastasis
Immunotherapy
発行日
2025-04
出版者
Karger
収録物名
Neuroendocrinology
巻(号)
115(3-4)
ページ
295-307
抄録
Introduction: Although neuroendocrine neoplasms (NENs) have a good prognosis, distant metastasis remains a crucial prognostic factor. Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, indicating poor prognosis. We aimed to evaluate the clinical significance and role of survivin as a therapeutic target for NEN. Methods: We assessed the cytotoxicity of Survivin-2B (a splicing variant of survivin) 80-88 specific CTL clone with HLA-A24 restriction against NEN cell lines using intracellular staining for interferon-gamma and assessed the frequency of Survivin-2B 80-88 CTL precursors in nine HLA-A24-positive patients with NEN using tetramer staining and compared it before and after resection. Finally, we evaluated the association between survivin expression and prognosis in 74 patients with pancreatic NEN using immunohistochemistry. Results: Survivin2B 80-88 CTL clone showed high cytotoxicity against QGP-1 (HLA-A24 positive) cocultured with the Survivin-2B 80-88 peptide. Only three patients were positive for tetramer staining; two showed decreased Survivin-2B 80-88 CTL precursor following resection. The nuclear survivin-low group had a significantly better prognosis than the nuclear survivinhigh group. Conclusion: Survivin in NEN is antigenic and may induce cellular immunity via the Survivin-2B CTL precursor. Survivin-targeting immunotherapy can be used to treat NEN with highly expressed Survivin-2B.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
This is the peer-reviewed but unedited manuscript version of the following article: Yuma Hane, Takahiro Tsuchikawa, Toru Nakamura, Kanako C. Hatanaka, Katsunori Sasaki, Noriko Kawai, Shintaro Takeuchi, Kimitaka Tanaka, Yoshitsugu Nakanishi, Toshimichi Asano, Takehiro Noji, Toshiaki Shichinohe, Yutaka Hatanaka, Yoshihiko Hirohshi, Toshihiko Torigoe, Satoshi Hirano; Survivin as a Therapeutic Target for Neuroendocrine Neoplasms. Neuroendocrinology 11 April 2025; 115 (3-4): 295–307 (DOI: 10.1159/000543270)]. The final, published version is available at http://karger.com/?doi=10.1159/000543270.
PISSN
0028-3835
EISSN
1423-0194
関連情報
PMID
39746333
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1159/000543270